Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials

CNBC reports that Eli Lilly has cleared two more late-stage trials for retatrutide, its next-generation obesity drug, with five total successful results to date. The company plans to file for regulatory approval in twenty twenty-seven as it expands its obesity treatment portfolio.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton